The Middle EAST Differentiated Thyroid Cancer Therapeutics Market was valued at USD 0.45 billion in 2024 and is projected to reach USD 1.20 billion by 2034, registering a CAGR of 10.0%. This growth trajectory is underpinned by several factors, including the rising incidence of differentiated thyroid cancer (DTC), advancements in therapeutic options, and increasing awareness regarding early...